期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 20, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/ijms20061283
关键词
chimeric antigen receptor; adoptive T cell therapy; cancer immunotherapy
资金
- international doctoral program i-Target: Immunotargeting of cancer - Elite Network of Bavaria
- Melanoma Research Alliance [N269626, 409510]
- Marie-Sklodowska-Curie Training Network for the Immunotherapy of Cancer (IMMUTRAIN) - H2020 program of the European Union
- Else Kroner-Fresenius-Stiftung
- German Cancer Aid
- Ernst-Jung-Stiftung
- LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative
- Bundesministerium fur Bildung und Forschung
- European Research Council [756017]
- European Research Council (ERC) [756017] Funding Source: European Research Council (ERC)
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen receptor (CAR) T cell therapy. CAR T cells mediate MHC-unrestricted tumor cell killing by enabling T cells to bind target cell surface antigens through a single-chain variable fragment (scFv) recognition domain. Upon engagement, CAR T cells form a non-classical immune synapse (IS), required for their effector function. These cells then mediate their anti-tumoral effects through the perforin and granzyme axis, the Fas and Fas ligand axis, as well as the release of cytokines to sensitize the tumor stroma. Their persistence in the host and functional outputs are tightly dependent on the receptor's individual componentsscFv, spacer domain, and costimulatory domainsand how said component functions converge to augment CAR T cell performance. In this review, we bring forth the successes and limitations of CAR T cell therapy. We delve further into the current understanding of how CAR T cells are designed to function, survive, and ultimately mediate their anti-tumoral effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据